NASDAQ:STSA Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.1450-Day Range$1.04▼$1.1152-Week Range$0.59▼$8.08Volume1.83 million shsAverage Volume701,788 shsMarket Capitalization$36.47 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaSustainability Satsuma Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside422.7% Upside$5.75 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.25Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.82) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector365th out of 966 stocksPharmaceutical Preparations Industry147th out of 434 stocks 3.0 Analyst's Opinion Consensus RatingSatsuma Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Satsuma Pharmaceuticals has a forecasted upside of 422.7% from its current price of $1.10.Amount of Analyst CoverageSatsuma Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for STSA. Previous Next 0.0 Dividend Strength Dividend YieldSatsuma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSatsuma Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSatsuma Pharmaceuticals has received a 67.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for Satsuma Pharmaceuticals is -1.25. Previous Next N/A News and Social Media Coverage Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Satsuma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Satsuma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.26% of the stock of Satsuma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Satsuma Pharmaceuticals are expected to decrease in the coming year, from ($0.82) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satsuma Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Satsuma Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatsuma Pharmaceuticals has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Satsuma Pharmaceuticals (NASDAQ:STSA) StockSatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More STSA Stock News HeadlinesAugust 30, 2023 | usnews.comSatsuma City High SchoolJune 9, 2023 | bizjournals.comJapanese pharma acquires its crash-strapped Durham spin-outOctober 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 8, 2023 | bizjournals.comJapanese pharma acquires its Durham spin-outMay 18, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineMay 3, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin NipponApril 25, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAOctober 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 22, 2023 | seekingalpha.comSTSA Satsuma Pharmaceuticals, Inc.April 21, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingApril 19, 2023 | msn.comAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More UpsideApril 18, 2023 | marketwatch.comSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAApril 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. BuyoutApril 17, 2023 | bizjournals.comPeninsula company bets big part of potential $221M sale on future of migraine drugApril 17, 2023 | markets.businessinsider.comSatsuma Pharma Agrees To Be Acquired By Shin Nippon BiomedicalApril 17, 2023 | msn.comSatsuma Skyrockets after Acquisition by Shin NipponApril 17, 2023 | investorplace.comWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?April 16, 2023 | finance.yahoo.comSNBL to Acquire Satsuma PharmaceuticalsMarch 30, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)March 30, 2023 | finance.yahoo.comWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn RateMarch 29, 2023 | bizjournals.comMigraine drug maker seeks FDA approval and a partner as it cuts jobsMarch 28, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsFebruary 18, 2023 | marketwatch.com8-K: Satsuma Pharmaceuticals, Inc.February 7, 2023 | reuters.comSTSA.OFebruary 2, 2023 | finance.yahoo.comSatsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma ConferenceDecember 28, 2022 | finance.yahoo.comDespite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For ApprovalSee More Headlines Receive STSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address STSA Company Calendar Last Earnings11/09/2021Today10/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryRegional Banks SectorMedical Current SymbolNASDAQ:STSA CUSIP85931930 CIK891106 Webwww.satsumarx.com Phone650-410-3200FaxN/AEmployees21Year Founded2016Price Target and Rating Average Stock Price Forecast$5.75 High Stock Price Forecast$15.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+422.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.24% Return on Assets-102.26% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book0.78Miscellaneous Outstanding Shares33,150,000Free Float22,809,000Market Cap$36.47 million OptionableNot Optionable Beta0.10 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. John A. Kollins MBA (Age 59)Pres, CEO & Director Comp: $830kMr. Thomas P. O'Neil (Age 57)Chief Financial Officer Comp: $550.08kDr. Detlef F. Albrecht (Age 61)Chief Medical Officer Comp: $625.97kMr. Mic Iwashima (Age 44)VP & Head of Operations Mr. Robert Schultz (Age 58)Sr. VP & Head of Chemistry, Manufacturing and Controls Dr. Shannon Strom Ph.D. (Age 46)VP & Head of Regulatory Affairs Mr. Robert M. JanoskyChief Commercial OfficerMore ExecutivesKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTNextCureNASDAQ:NXTCFortress BiotechNASDAQ:FBIOMainz BiomedNASDAQ:MYNZLeap TherapeuticsNASDAQ:LPTXView All CompetitorsInsidersKen TakanashiBought 22,053,581 shares on 6/6/2023Total: $20.07 M ($0.91/share)Braden Michael LeonardBought 150,000 shares on 11/21/2022Total: $106,500.00 ($0.71/share)Braden Michael LeonardBought 5,608,306 shares on 11/14/2022Total: $3.87 M ($0.69/share)View All Insider Transactions STSA Stock - Frequently Asked Questions Should I buy or sell Satsuma Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares. View STSA analyst ratings or view top-rated stocks. What is Satsuma Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 1 year price objectives for Satsuma Pharmaceuticals' shares. Their STSA share price forecasts range from $2.00 to $15.00. On average, they expect the company's share price to reach $5.75 in the next year. This suggests a possible upside of 422.7% from the stock's current price. View analysts price targets for STSA or view top-rated stocks among Wall Street analysts. How were Satsuma Pharmaceuticals' earnings last quarter? Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) announced its quarterly earnings data on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. What other stocks do shareholders of Satsuma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA). When did Satsuma Pharmaceuticals IPO? (STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO. What is Satsuma Pharmaceuticals' stock symbol? Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA." What is Satsuma Pharmaceuticals' stock price today? One share of STSA stock can currently be purchased for approximately $1.10. How much money does Satsuma Pharmaceuticals make? Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $36.47 million. The financial services provider earns $-70,060,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. How can I contact Satsuma Pharmaceuticals? Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com. This page (NASDAQ:STSA) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.